TA216 Leukaemia (lymphocytic) - bendamustine: review decision - March 2014
Review of NICE Technology Appraisal Guidance No. 216; Bendamustine for the treatment of chronic lymphocytic leukaemia
The Institute was proposing the TA216 should be moved to the static list.
During consultation, the majority of comments received by the Institute agreed with the proposal put forward. After consideration of all of the comments (attached as appendix A), the Institute’s Guidance Executive has decided to proceed with the proposal.
Consequently, TA216 will be moved to the list of static technology appraisals. Topics on the static list can be considered for review if any new evidence becomes available that is likely to lead to a change in the existing recommendations.
This page was last updated: 25 March 2014